32 search results for: CRSwNP

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

30 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

IRS-ISIAN 2024 | Guideline Definitions of Control in <b>CRSwNP</b>

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

Loss of Smell is a Key Symptom of <b>CRSwNP</b>

interactivity

Loss of Smell is a Key Symptom of CRSwNP

5 min

Rhinology

Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

Why did the definition of control in <b>CRSwNP</b> change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

2 min

Rhinology

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in <b>CRSwNP</b>?

expert video

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

5 min

Rhinology

Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission

What contributes more to loss of smell in patients with <b>CRSwNP</b>: nasal obstruction or inflammation?

expert video

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

5 min

Rhinology

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

15 min

Rhinology

Profs. Wytske Fokkens and Joaquim Mullol discuss the clinical significance of the loss of smell in patients with CRSwNP.

Podcast

ADVENT On Air | Remission in CRSwNP

19 min

Rhinology

Prof. Peter Hellings and Dr. Stella Lee discuss the concept of remission for patients with chronic rhinosinusitis with nasal polyps.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: PolandChange country/region